Life sciences company ValiRx has announced plans to raise up to £1.05 million through a mix of placing, retail offer and director subscriptions to support its oncology and women’s health research.

The fundraise, priced at 0.25p per share, includes warrants allowing investors to double their stake at 0.5p per share over three years.

The Nottingham-based MedTech expects to use the proceeds to expand its collaborative research pipeline and progress preclinical programmes such as Cytolytix, VAL201 2.0 and the 3K screen through its subsidiary Inaphaea Biolabs.

Chairman Martin Gouldstone said the raise comes despite a “difficult funding environment,” while CEO Mark Eccleston added that the new capital will help deliver “significant value accretion throughout 2026”.